RETINALAMIN - RETINA CELL ACTIVATOR

RETINALAMIN® refers to the pharmacotherapeutic stimulators of tissue regeneration. The mechanism of action is determined by the metabolic activity of Retinalamin®: the drug activates eye tissue metabolism, normalizes the functions of cellular membranes, improves intracellular synthesis of protein, regulates the processes of lipid peroxide oxidation, and optimizes energy processes due to strengthened activity of Muller’s cells and glutamate inactivation. It improves the functional interaction between the pigment epithelium and outer segments of visual receptors, normalizes vascular permeability, prevents oxidative stress and excitotoxicity, improves metabolism in ocular tissues and blood flow in ocular vessels.

Retinalamin activates retinal cells reserves increasing cell survivability and regenerative capacity when retina and optic nerve has been damaged. Retinalamin increases metabolism and blood flow, optimizes vascular permeability in eyes. It improves and stabilizes visual functions (visual acuity, low-light eyesight, visual field extension). The data is supported by specific retina and optic nerve studies. Pharmaceutical Company GEROPHARM is a sole manufacturer of Retinalamin. The drug is manufactured using the Company's own patented technology.

Retinoprotectors are agents that protect retina from damage caused by exogenous and endogenous forces thus safeguarding eyesight from getting worse. Searching for new agents for retinal protection is a complicated process which requires integrated efforts of therapists, biologists and pharmacologists. Special attention should be given to peptide drugs. The benefits of these drugs are tissue specificity, absence of significant side-effects, short-course treatment and long-term clinical effect. Retinalamin® is an example of successful drug development based on these principles. The effecacy of Retinalamin® has been proven at the cellular and molecular levels. Retinal injuries may be caused by various factors and have different disease patterns, however, they are all accompanied by death of retinal neurons due to pathological processes with the similar molecular mechanisms. Among those mechanisms the most predominant one is excitotoxicity caused by overstimulation of glutamate receptors followed by the influx of calcium ions. Excessive Ca2+ concentration triggers processes of cell death via necrosis or apoptosis.

GEROPHARM is the only manufacturer of original drug Retinalamin®

Usage:

• compensated primary ppen-angle glaucoma,
• diabetic retinopathy,
• post-traumatic and post-inflammatory central retinal dystrophy (macular dystrophy),
• central retinal dystrophy (macular dystrophy),
• myopia (within comprehensive treatment),
• central and peripheral tapetoretinal abiotrophy.

Pharmacodynamics:

Retinalamin is a complex of water-soluble polypeptide fractions with the molecular weight of no more than 10,000 kDa. The agent has a stimulating effect on retinal photoreceptors and cellular elements, improves functional interaction between pigment epithelium and outer segments of photoreceptors, glial cells in patients with retinal dystrophy and accelerates recovery of light sensitivity processes in the retina. It normalizes vascular permeability, reduces local inflammation, and activates reparative processes in patients with diseases and traumas of the retina.

Indications for use:

compensated primary open-angle glaucoma, diabetic retinopathy, post-traumatic and post-inflammatory central retinal dystrophy, central retinal dystrophy, myopia (within comprehensive treatment), central and peripheral tapetoretinal abiotrophy.

Contraindications:

individual hypersensitivity to any of the medication components, in patients under 18 with compensated primary open-angle glaucoma, diabetic retinopathy, myopia (due to lack of efficacy and safety data); in patients under 12 months with post-traumatic and post-inflammatory central retinal dystrophy, central and peripheral tapetoretinal abiotrophy.

Ingredients:

each vial contains: drug substance – Retinalamin 5 mg (complex of water-soluble polypeptide fractions), excipient – Glycine 17 mg (stabilizer).

Dosage:

in adults with diabetic retinopathy, post-traumatic and post-inflammatory central retinal dystrophy, central and peripheral tapetoretinal abiotrophy: parabulbar or intramuscular injections of 5–10 mg once a day. Treatment duration is 5–10 days; if necessary, it is repeated after 3–6 months. In patients with compensated primary open-angle glaucoma: parabulbar or intramuscular injections of 5 mg once a day. Treatment duration is 10 days; if necessary, it is repeated after 3–6 months. In patients with myopia: parabulbar injections of 5 mg once a day. Treatment duration is 10 days.

Form release:

lyophilisate for preparation of solution for intramuscular and parabulbar injections 10 vials of 5mg

Guaranteed authenticity and quality:

100% Original from GEROPHARM (Russian Federation)

Development and production:

GEROPHARM (Russian Federation)

St. Petersburg Institute of Bioregulation and Gerontology